Literature DB >> 2875247

Protective efficacy of BCG against leprosy in Northern Malawi.

P E Fine, J M Ponnighaus, N Maine, J A Clarkson, L Bliss.   

Abstract

The effectiveness of a BCG vaccination programme in protecting against leprosy was assessed by case-control and cohort analyses of data from the Lepra Evaluation Project in Karonga District, Northern Malawi. Results indicate that BCG provides at least 50% protection against leprosy in this population and that protection is independent of age, sex, schooling status, or location within the project area. Agreement between these findings and those from a controlled trial in Uganda indicates that BCG is sufficiently effective against leprosy in East and Central Africa to be considered an important element of leprosy control in that region.

Mesh：

Substances：

Year:  1986        PMID： 2875247     DOI： 10.1016/s0140-6736(86)90367-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  13 in total

1.  BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea, 1963-79.

Authors:  A Bagshawe; G C Scott; D A Russell; S C Wigley; A Merianos; G Berry
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

2.  The etiologic agents of leprosy and tuberculosis share an immunoreactive protein antigen with the vaccine strain Mycobacterium bovis BCG.

Authors:  T M Shinnick; D Sweetser; J Thole; J van Embden; R A Young
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

3.  Epidemiology of Tuberculosis in Malawi.

Authors:  Thomas Nyirenda
Journal:  Malawi Med J       Date:  2006-09       Impact factor: 0.875

4.  Protective efficacy of BCG vaccine against leprosy in southern Malaŵi.

Authors:  D M Baker; J S Nguyen-Van-Tam; S J Smith
Journal:  Epidemiol Infect       Date:  1993-08       Impact factor: 2.451

5.  Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection.

Authors:  R Hernandez-Pando; L Pavön; K Arriaga; H Orozco; V Madrid-Marina; G Rook
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  T-cell-mediated cytotoxicity against Mycobacterium antigen-pulsed autologous macrophages in leprosy patients.

Authors:  M C Sasiain; S de la Barrera; F Minnucci; R Valdez; M M de Elizalde de Bracco; L M Baliña
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

7.  The distribution and implications of BCG scars in northern Malawi.

Authors:  P E Fine; J M Ponnighaus; N Maine
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

8.  Immune profiling of leprosy and tuberculosis patients to 15-mer peptides of Mycobacterium leprae and M. tuberculosis GroES in a BCG vaccinated area: implications for development of vaccine and diagnostic reagents.

Authors:  Rabia Hussain; Firdaus Shahid; Shahid Zafar; Maqboola Dojki; Hazel M Dockrell
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

9.  Evidence that the Mitsuda reaction to Mycobacterium leprae can be mediated by lymphocytes responsive to Mycobacterium tuberculosis.

Authors:  P P Roberts; H M Dockrell; K P McAdam
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

Review 10.  BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.

Authors:  Alok K Singh; Mihai G Netea; William R Bishai
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.